Cover Image
市場調查報告書

色素性視網膜炎(視網膜炎):開發平台分析

Retinitis Pigmentosa (Retinitis) - Pipeline Review, H1 2016

出版商 Global Markets Direct 商品編碼 200486
出版日期 內容資訊 英文 178 Pages
訂單完成後即時交付
價格
Back to Top
色素性視網膜炎(視網膜炎):開發平台分析 Retinitis Pigmentosa (Retinitis) - Pipeline Review, H1 2016
出版日期: 2016年06月08日 內容資訊: 英文 178 Pages
簡介

色素性視網膜炎(RP),是作用於視網膜的一連串遺傳性眼科疾病的通稱。RP會對光受體細胞(視網膜內部偵測光的細胞)造成破壞,由於光受體細胞具有捕捉、處理光線使眼睛有看見東西的效果,光受體細胞遭到破壞、壞死將導致視力逐漸喪失。各種RP的共通特徵更是視桿細胞(偵測微光的視網膜細胞)和錐體細胞(偵測光、色彩的視網膜細胞)逐漸喪失,不過最初階段大部分是喪失視桿細胞。這種形態的RP(也叫桿錐細胞退化),會先從夜盲症開始。所謂夜盲症,是類似於我們從明亮的戶外進入黑暗的電影院中所感到的感覺那樣的症狀。

本報告提供全球各國的色素性視網膜炎(視網膜炎)所用的開發中產品之開發情形相關分析,提供您開發中產品的最新趨勢,及臨床實驗的各階段產品一覽,主要企業簡介,主要藥物概要(產品概要,功能機制,研究開發(R&D)的發展情形),最新的產業趨勢等調查。

簡介

  • 分析範圍

色素性視網膜炎(視網膜炎)概要

治療藥的開發

  • 色素性視網膜炎(視網膜炎)開發中產品:概要
  • 色素性視網膜炎(視網膜炎)開發中產品:比較分析

各企業正在開發的色素性視網膜炎(視網膜炎)治療藥

大學/研究機關研究中的色素性視網膜炎(視網膜炎)治療藥

開發中產品的概要

  • 後期階段的產品
  • 臨床實驗階段的產品
  • 初期階段的產品

色素性視網膜炎(視網膜炎)治療藥:開發中的產品一覽(各企業)

色素性視網膜炎(視網膜炎)治療藥:研究中的產品一覽(各大學/研究機關)

色素性視網膜炎(視網膜炎)開發治療藥的企業

  • Acucela Inc.
  • Amarantus Bioscience Holdings, Inc.
  • Amgen Inc.
  • Applied Genetic Technologies Corporation
  • Asklepios BioPharmaceutical, Inc.
  • Astellas Pharma Inc.
  • Caladrius Biosciences, Inc.
  • Dompe Farmaceutici S.p.A.
  • Genable Technologies Limited
  • Genethon
  • GenSight Biologics S.A.
  • Grupo Ferrer Internacional, S.A.
  • ID Pharma Co., Ltd.
  • InFlectis BioScience
  • International Stem Cell Corporation
  • Ionis Pharmaceuticals, Inc.
  • M's Science Corporation
  • Mimetogen Pharmaceuticals Inc.
  • Nanovector s.r.l.
  • Orphagen Pharmaceuticals, Inc.
  • QLT Inc.
  • RegenxBio Inc.
  • ReNeuron Group Plc
  • SanBio, Inc.
  • Sanofi
  • Shire Plc
  • Spark Therapeutics, Inc.
  • Staidson (Beijing) Biopharmaceuticals Co.,td.
  • Sucampo Pharmaceuticals, Inc.
  • Sun Pharma Advanced Research Company Ltd

肝臟病:治療藥的評估

  • 單劑治療藥的情況
  • 標的別
  • 各行動機制
  • 各投藥法
  • 各分子類型

藥物簡介

肝臟病治療藥:最新的開發平台趨勢

肝臟病治療藥:開發暫停的產品

肝臟病治療藥:開發中止的產品

肝臟病相關產品的開發的里程碑

  • 值得注意的最新趨勢·新聞稿

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC8168IDB

Summary

Global Markets Direct's, 'Retinitis Pigmentosa (Retinitis) - Pipeline Review, H1 2016', provides an overview of the Retinitis Pigmentosa (Retinitis) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Retinitis Pigmentosa (Retinitis), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Retinitis Pigmentosa (Retinitis) and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Retinitis Pigmentosa (Retinitis)
  • The report reviews pipeline therapeutics for Retinitis Pigmentosa (Retinitis) by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Retinitis Pigmentosa (Retinitis) therapeutics and enlists all their major and minor projects
  • The report assesses Retinitis Pigmentosa (Retinitis) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Retinitis Pigmentosa (Retinitis)

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Retinitis Pigmentosa (Retinitis)
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Retinitis Pigmentosa (Retinitis) pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
  • Introduction
  • Retinitis Pigmentosa (Retinitis) Overview
  • Therapeutics Development
  • Retinitis Pigmentosa (Retinitis) - Therapeutics under Development by Companies
  • Retinitis Pigmentosa (Retinitis) - Therapeutics under Investigation by Universities/Institutes
  • Retinitis Pigmentosa (Retinitis) - Pipeline Products Glance
  • Retinitis Pigmentosa (Retinitis) - Products under Development by Companies
  • Retinitis Pigmentosa (Retinitis) - Products under Investigation by Universities/Institutes
  • Retinitis Pigmentosa (Retinitis) - Companies Involved in Therapeutics Development
  • Retinitis Pigmentosa (Retinitis) - Therapeutics Assessment
  • Drug Profiles
  • Retinitis Pigmentosa (Retinitis) - Recent Pipeline Updates
  • Retinitis Pigmentosa (Retinitis) - Dormant Projects
  • Retinitis Pigmentosa (Retinitis) - Discontinued Products
  • Retinitis Pigmentosa (Retinitis) - Product Development Milestones
  • Appendix

List of Tables

  • Number of Products under Development for Retinitis Pigmentosa (Retinitis), H1 2016
  • Number of Products under Development for Retinitis Pigmentosa (Retinitis) - Comparative Analysis, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Number of Products under Development by Companies, H1 2016 (Contd..1)
  • Number of Products under Investigation by Universities/Institutes, H1 2016
  • Comparative Analysis by Late Stage Development, H1 2016
  • Comparative Analysis by Clinical Stage Development, H1 2016
  • Comparative Analysis by Early Stage Development, H1 2016
  • Products under Development by Companies, H1 2016
  • Products under Development by Companies, H1 2016 (Contd..1)
  • Products under Development by Companies, H1 2016 (Contd..2)
  • Products under Investigation by Universities/Institutes, H1 2016
  • Retinitis Pigmentosa (Retinitis) - Pipeline by Acucela Inc., H1 2016
  • Retinitis Pigmentosa (Retinitis) - Pipeline by Amarantus Bioscience Holdings, Inc., H1 2016
  • Retinitis Pigmentosa (Retinitis) - Pipeline by Amgen Inc., H1 2016
  • Retinitis Pigmentosa (Retinitis) - Pipeline by Applied Genetic Technologies Corporation, H1 2016
  • Retinitis Pigmentosa (Retinitis) - Pipeline by Asklepios BioPharmaceutical, Inc., H1 2016
  • Retinitis Pigmentosa (Retinitis) - Pipeline by Astellas Pharma Inc., H1 2016
  • Retinitis Pigmentosa (Retinitis) - Pipeline by Caladrius Biosciences, Inc. , H1 2016
  • Retinitis Pigmentosa (Retinitis) - Pipeline by Dompe Farmaceutici S.p.A., H1 2016
  • Retinitis Pigmentosa (Retinitis) - Pipeline by Genable Technologies Limited, H1 2016
  • Retinitis Pigmentosa (Retinitis) - Pipeline by Genethon, H1 2016
  • Retinitis Pigmentosa (Retinitis) - Pipeline by GenSight Biologics S.A., H1 2016
  • Retinitis Pigmentosa (Retinitis) - Pipeline by Grupo Ferrer Internacional, S.A., H1 2016
  • Retinitis Pigmentosa (Retinitis) - Pipeline by ID Pharma Co., Ltd., H1 2016
  • Retinitis Pigmentosa (Retinitis) - Pipeline by InFlectis BioScience, H1 2016
  • Retinitis Pigmentosa (Retinitis) - Pipeline by International Stem Cell Corporation, H1 2016
  • Retinitis Pigmentosa (Retinitis) - Pipeline by Ionis Pharmaceuticals, Inc., H1 2016
  • Retinitis Pigmentosa (Retinitis) - Pipeline by M's Science Corporation, H1 2016
  • Retinitis Pigmentosa (Retinitis) - Pipeline by Mimetogen Pharmaceuticals Inc., H1 2016
  • Retinitis Pigmentosa (Retinitis) - Pipeline by Nanovector s.r.l., H1 2016
  • Retinitis Pigmentosa (Retinitis) - Pipeline by Orphagen Pharmaceuticals, Inc., H1 2016
  • Retinitis Pigmentosa (Retinitis) - Pipeline by QLT Inc., H1 2016
  • Retinitis Pigmentosa (Retinitis) - Pipeline by RegenxBio Inc., H1 2016
  • Retinitis Pigmentosa (Retinitis) - Pipeline by ReNeuron Group Plc, H1 2016
  • Retinitis Pigmentosa (Retinitis) - Pipeline by SanBio, Inc., H1 2016
  • Retinitis Pigmentosa (Retinitis) - Pipeline by Sanofi, H1 2016
  • Retinitis Pigmentosa (Retinitis) - Pipeline by Shire Plc, H1 2016
  • Retinitis Pigmentosa (Retinitis) - Pipeline by Spark Therapeutics, Inc., H1 2016
  • Retinitis Pigmentosa (Retinitis) - Pipeline by Staidson (Beijing) Biopharmaceuticals Co., Ltd., H1 2016
  • Retinitis Pigmentosa (Retinitis) - Pipeline by Sucampo Pharmaceuticals, Inc., H1 2016
  • Retinitis Pigmentosa (Retinitis) - Pipeline by Sun Pharma Advanced Research Company Ltd., H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Number of Products by Stage and Target, H1 2016
  • Number of Products by Stage and Mechanism of Action, H1 2016
  • Number of Products by Stage and Route of Administration, H1 2016
  • Number of Products by Stage and Molecule Type, H1 2016
  • Retinitis Pigmentosa (Retinitis) Therapeutics - Recent Pipeline Updates, H1 2016
  • Retinitis Pigmentosa (Retinitis) - Dormant Projects, H1 2016
  • Retinitis Pigmentosa (Retinitis) - Discontinued Products, H1 2016 166List of Figures
  • Number of Products under Development for Retinitis Pigmentosa (Retinitis), H1 2016
  • Number of Products under Development for Retinitis Pigmentosa (Retinitis) - Comparative Analysis, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Number of Products under Investigation by Universities/Institutes, H1 2016
  • Comparative Analysis by Clinical Stage Development, H1 2016
  • Comparative Analysis by Early Stage Products, H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Number of Products by Top 10 Targets, H1 2016
  • Number of Products by Stage and Top 10 Targets, H1 2016
  • Number of Products by Top 10 Mechanism of Actions, H1 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016
  • Number of Products by Routes of Administration, H1 2016
  • Number of Products by Stage and Routes of Administration, H1 2016
  • Number of Products by Top 10 Molecule Types, H1 2016
  • Number of Products by Stage and Top 10 Molecule Types, H1 2016

List of Figures

  • Number of Products under Development for Retinitis Pigmentosa (Retinitis), H1 2016
  • Number of Products under Development for Retinitis Pigmentosa (Retinitis) - Comparative Analysis, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Number of Products under Investigation by Universities/Institutes, H1 2016
  • Comparative Analysis by Clinical Stage Development, H1 2016
  • Comparative Analysis by Early Stage Products, H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Number of Products by Top 10 Targets, H1 2016
  • Number of Products by Stage and Top 10 Targets, H1 2016
  • Number of Products by Top 10 Mechanism of Actions, H1 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016
  • Number of Products by Routes of Administration, H1 2016
  • Number of Products by Stage and Routes of Administration, H1 2016
  • Number of Products by Top 10 Molecule Types, H1 2016
  • Number of Products by Stage and Top 10 Molecule Types, H1 2016
Back to Top